Clinical trials: Oesophageal Cancer Metastatic
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
This study is being done to see if tucatinib with trastuzumab, ramucirumab and paclitaxel works better than ramucirumab and paclitaxel to treat HER2-positive (HER2+) cancer of the gut (stomach or gastroesophageal cancer).
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- MOUNTAINEER-02 (NCT04499924)
- Testing
- tucatinib, trastuzumab, ramucirumab
- Where
- 48 sites in United States, Australia and 4 more
- Volunteers
- 17 people
- Sponsor
- Seagen Inc.
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
A Phase Ib/II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with locally…
- Trial name
- NCT03281369
- Testing
- 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 219 people
- Sponsor
- Hoffmann-La Roche
Esophageal Squamous Cell Carcinoma
Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer
The aim of this study is to explore whether FOLFOX6 as treatment could improve the time to progression (TTP) and overall survival (OS) of the patient with recurrent or metastatic esophagus.
- Trial name
- NCT01605305
- Testing
- FOLFOX6
- Volunteers
- 60 people
- Sponsor
- Fudan University
Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as…
- Conditions
- Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06585488
- Testing
- BGB-53038, Tislelizumab, Cetuximab
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Esophageal Squamous Cell Carcinoma
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
This is a randomized, double-blind multi-center, phase III study comparing the efficacy and safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in subjects with unresectable, locally advanced…
- Trial name
- NCT03748134
- Testing
- Sintilimab, Cisplatin, Paclitaxel
- Where
- 48 sites in United States, Australia and 5 more
- Volunteers
- 746 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
OESOPHAGO-GASTRIC CARCINOMA
PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA
Gastric cancer is the fourth commonest cancer and the second largest cause of mortality from cancer. Surgical resection of localised forms of gastric cancer offers the only chance of a cure.
- Trial name
- GASTFOX (NCT03006432)
- Testing
- Oxaliplatin, 5Fluorouracil bolus, 5Fluorouracil continu
- Where
- 134 sites in France, Martinique
- Volunteers
- 507 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Foregut Adenocarcinoma, Esophageal Adenocarcinoma
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with intervenable oligometastatic (stage IV) cancer of…
- Conditions
- Foregut Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- OLIGOMETS (NCT07282912)
- Testing
- Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Yale University
Esophageal Cancer
An Observational Study to Evaluate Lymph Metastases and Prognoses of the Patients With Esophageal Cancer
The real-world observational study was designed to explore lymph metastases and prognoses of the Chinese patients with thoracic T1-T3 esophageal cancer
- Trial name
- NCT03415815
- Testing
- Surgeries
- Where
- 10 sites in China
- Volunteers
- 3,673 people
- Sponsor
- Henan Cancer Hospital
Esophageal Cancer, Gastric Cancer
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
The purpose of this study is to determine the safety and effectiveness of a combination of chemotherapy, capecitabine and oxaliplatin, plus the antibodies bevacizumab and trastuzumab.
- Trial name
- NCT01191697
- Testing
- bevacizumab, trastuzumab, oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Esophageal Squamous Cell Carcinoma
Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003）
Retrospective studies suggested that the addition of thoracic concurrent chemoradiotherapy to systemic chemotherapy improved the survival and quality of life (QOL) of patients with metastatic esophageal squamous cell carcinoma…
- Trial name
- EC-CRT-003 (NCT05512520)
- Testing
- Intensity-modulated radiotherapy concurrent with capecitabine
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Sun Yat-sen University
Solid Tumor, KRAS Mutation
A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus
This study is no longer open to new participants. It was a study in adults with advanced cancer in the stomach and oesophagus. This is a study for people for whom previous treatment was not successful or no treatment exists.
- Trial name
- NCT06056024
- Testing
- BI 3706674
- Where
- 17 sites in United States, Japan and 2 more
- Volunteers
- 47 people
- Sponsor
- Boehringer Ingelheim
Esophageal Squamous Cell Carcinoma
Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy
Phase II Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Squamous Carcinoma After Failure of Conventional Chemotherapy.
- Trial name
- NCT01973725
- Testing
- Icotinib Hydrochloride
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yuhong Li
Esophageal Cancer
Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00093652
- Testing
- gefitinib, oxaliplatin, conventional surgery
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Malignant Germ Cell Tumor, Lung Adenocarcinoma
DBC-664 in Adult Patients With Solid Tumors
DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian…
- Conditions
- Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
- Trial name
- NCT07705035
- Testing
- DBC-664
- Where
- 7 sites in United States
- Volunteers
- 210 people
- Sponsor
- Duboce Biopharmaceuticals, Inc.
Esophageal Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002984
- Testing
- cisplatin, fluorouracil, paclitaxel
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Esophageal Squamous Cell Carcinoma Metastatic
A Study of SBRT for OligoMetastatic ESCC
The aim of this phase II trial is to assess progress-free survival, local control, overall survival, safety and tolerability of SBRT to treat patients with oligometastases in esophageal squamous cell carcinoma.
- Trial name
- NCT03000816
- Testing
- SBRT
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Fudan University
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects with Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT04086758
- Testing
- zolbetuximab
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma China, Inc.
Pancreatic Cancer, Hepatocellular Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer
- Trial name
- NCT05070247
- Testing
- TAK-500, Pembrolizumab, Tocilizumab
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Takeda
ESCC or Esophageal Adenosquamous Carcinoma
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC
This study is conducted in patients with Locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma (ESCC) or esophageal adenosquamous carcinoma. This study includes three arms: A, B1, and B2.
- Trial name
- NCT05221658
- Testing
- HLX07+HLX10+ Cisplatin+5-FU, HLX07
- Where
- 17 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai Henlius Biotech
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)